GlassScriptPhysician profile
Minh-Thy Le
NPI 1336907815
$1,683.13
in general payments reported to CMS, 2019-2025
26 companies · $1,624 in 2025
The $1,624 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $59.22 · 2025: $1,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.37 |
| Education | $158.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $320.39 | 2025 | Lynparza, Fasenra, Tezspire |
| Csl Behring | $239.35 | 2025 | Andembry |
| Regeneron Healthcare Solutions, INC. | $221.97 | 2025 | Dupixent, Libtayo |
| Eisai INC. | $98.16 | 2025 | |
| Merck Sharp & Dohme LLC | $69.08 | 2024-2025 | Keytruda, Lynparza |
| Genmab U.S., INC. | $65.78 | 2025 | Tivdak, Epkinly |
| Stemline Therapeutics INC. | $59.84 | 2025 | Orserdu, Elzonris |
| Genzyme Corporation | $58.30 | 2025 | |
| Novartis Pharmaceuticals Corporation | $57.42 | 2025 | |
| Sobi, INC | $50.27 | 2025 | |
| Abbvie INC. | $49.87 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $44.71 | 2025 | Neffy |
| Servier Pharmaceuticals LLC | $43.14 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.98 | 2025 | Fruzaqla, Takhzyro |
| Adc Therapeutics America, INC. | $31.88 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $27.18 | 2025 | |
| Galderma Laboratories, L.P. | $26.79 | 2025 | Nemluvio |
| Array Biopharma INC | $23.27 | 2025 | Braftovi, Tukysa, Mektovi |
| Pharmacosmos Therapeutics INC. | $22.76 | 2025 | Monoferric |
| Daiichi Sankyo INC. | $22.29 | 2025 | Enhertu |
| Geron Corporation | $20.60 | 2025 | Rytelo |
| Leo Pharma INC. | $20.18 | 2025 | Anzupgo |
| Karyopharm Therapeutics INC. | $20.09 | 2025 | Xpovio |
| Novocure INC. | $19.47 | 2025 | Optune Gio |
| Caris Mpi, INC. | $18.07 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $17.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minh-Thy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.